Editas Medicine Stock Performance
| EDIT Stock | USD 1.37 0.02 1.44% |
On a scale of 0 to 100, Editas Medicine holds a performance score of 4. The firm shows a Beta (market volatility) of 3.71, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Editas Medicine will likely underperform. Please check Editas Medicine's kurtosis, day typical price, as well as the relationship between the potential upside and total risk alpha , to make a quick decision on whether Editas Medicine's price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Editas Medicine are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating forward indicators, Editas Medicine unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Scadden David of 25000 shares of Editas Medicine at 9.55 subject to Rule 16b-3 | 01/15/2025 |
2 | Chinese biotech says it will start first in vivo beta-thalassemia trial | 01/22/2025 |
3 | Acquisition by Oneill Gilmore Neil of 130700 shares of Editas Medicine subject to Rule 16b-3 | 02/07/2025 |
4 | Editas Medicine to Announce Fourth QuarterFull Year 2024 Financial Results and to Participate in Investor Conferences in March | 02/24/2025 |
5 | Mirum Pharmaceuticals, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/26/2025 |
6 | JULIENS AUCTIONS BOLD LUXURY THE LIMELIGHT EDIT | 02/28/2025 |
7 | Disposition of 2891 shares by Linda Burkly of Editas Medicine at 1.7107 subject to Rule 16b-3 | 03/04/2025 |
8 | Editas Medicine Inc Reports Q4 2024 Loss of 0.55 EPS and 30.6 Million Revenue, Missing Estimates | 03/05/2025 |
9 | Editas Q4 Loss Wider Than Expected, Revenues Fall YY, Stock Down | 03/06/2025 |
10 | Heres Why Editas Medicine Must Use Its Cash Wisely | 03/13/2025 |
11 | Editas Medicine promotes Amy Parison as CFO | 03/20/2025 |
| Begin Period Cash Flow | 127.5 M |
Editas |
Editas Medicine Relative Risk vs. Return Landscape
If you would invest 125.00 in Editas Medicine on December 21, 2024 and sell it today you would earn a total of 3.00 from holding Editas Medicine or generate 2.4% return on investment over 90 days. Editas Medicine is currently generating 0.7657% in daily expected returns and assumes 13.5361% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Editas, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Editas Medicine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Editas Medicine's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Editas Medicine, and traders can use it to determine the average amount a Editas Medicine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0566
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EDIT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.54 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.77 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Editas Medicine is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Editas Medicine by adding it to a well-diversified portfolio.
Editas Medicine Fundamentals Growth
Editas Stock prices reflect investors' perceptions of the future prospects and financial health of Editas Medicine, and Editas Medicine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Editas Stock performance.
| Return On Equity | -0.98 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (1.12) % | ||||
| Current Valuation | (121.2 M) | ||||
| Shares Outstanding | 82.98 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 3.52 X | ||||
| Revenue | 32.31 M | ||||
| Gross Profit | (166.93 M) | ||||
| EBITDA | (233.11 M) | ||||
| Net Income | (237.09 M) | ||||
| Cash And Equivalents | 452.56 M | ||||
| Cash Per Share | 6.59 X | ||||
| Total Debt | 35.03 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 12.67 X | ||||
| Book Value Per Share | 1.62 X | ||||
| Cash Flow From Operations | (210.28 M) | ||||
| Earnings Per Share | (2.88) X | ||||
| Market Capitalization | 113.68 M | ||||
| Total Asset | 341.59 M | ||||
| Retained Earnings | (1.47 B) | ||||
| Working Capital | 212.09 M | ||||
| Current Asset | 144.99 M | ||||
| Current Liabilities | 6.92 M | ||||
About Editas Medicine Performance
Assessing Editas Medicine's fundamental ratios provides investors with valuable insights into Editas Medicine's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Editas Medicine is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -6.2 K | -5.9 K | |
| Return On Tangible Assets | (0.69) | (0.73) | |
| Return On Capital Employed | (0.95) | (1.00) | |
| Return On Assets | (0.69) | (0.73) | |
| Return On Equity | (1.77) | (1.68) |
Things to note about Editas Medicine performance evaluation
Checking the ongoing alerts about Editas Medicine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Editas Medicine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Editas Medicine is way too risky over 90 days horizon | |
| Editas Medicine may become a speculative penny stock | |
| Editas Medicine appears to be risky and price may revert if volatility continues | |
| Editas Medicine has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 32.31 M. Net Loss for the year was (237.09 M) with loss before overhead, payroll, taxes, and interest of (166.93 M). | |
| Editas Medicine currently holds about 452.56 M in cash with (210.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: Editas Medicine promotes Amy Parison as CFO |
- Analyzing Editas Medicine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Editas Medicine's stock is overvalued or undervalued compared to its peers.
- Examining Editas Medicine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Editas Medicine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Editas Medicine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Editas Medicine's stock. These opinions can provide insight into Editas Medicine's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.